A field-tested LOI framework built for sterile and non-sterile compounding pharmacy acquisitions — covering regulatory contingencies, prescriber retention earnouts, pharmacist-in-charge transitions, and SBA-compatible deal structures.
Acquiring a compounding pharmacy is materially different from buying a standard retail pharmacy. The regulatory environment — dual oversight from state boards and the FDA, USP 795/797/800 compliance requirements, and PCAB accreditation standards — creates contingencies and representations that must be embedded in the LOI before a purchase agreement is ever drafted. Prescriber relationships are the economic engine of most compounding practices, yet they are informal, personal, and not contractually guaranteed, making earnout provisions tied to referral retention one of the most contested terms in any compounding pharmacy deal. Cleanroom infrastructure, beyond-use dating policies, and pharmacist-in-charge licensure further complicate what might otherwise appear to be a straightforward healthcare services acquisition. This LOI template and guide addresses every major negotiation point specific to compounding pharmacy transactions in the $1M–$5M revenue range, including SBA 7(a) financing compatibility, equity rollover structures, and regulatory tail risk allocation.
Find Compounding Pharmacy Businesses to AcquireParties and Transaction Structure
Identifies buyer and seller entities, clarifies whether the transaction is structured as an asset purchase or stock purchase, and establishes which licenses, permits, and accreditations are being transferred or assumed.
Example Language
This Letter of Intent is entered into between [Buyer Entity], a [State] [LLC/Corporation] ('Buyer'), and [Seller Entity], a [State] [LLC/Corporation] ('Seller'), regarding Buyer's proposed acquisition of substantially all assets of [Pharmacy Name], a PCAB-accredited compounding pharmacy located at [Address] ('the Business'). The transaction is contemplated as an asset purchase, including all compounding equipment, cleanroom fixtures, inventory, customer and prescriber records, SOPs, proprietary formulations, and goodwill, but excluding accounts receivable generated prior to the closing date. Seller's state pharmacy board license, DEA registration, and any applicable state controlled substance licenses will be addressed in the transition services agreement, with Buyer required to obtain independent licensure prior to closing.
💡 Asset purchase structures are strongly preferred by buyers in compounding pharmacy deals because they avoid inheriting unknown regulatory liabilities, prior FDA 483 observations, or state board disciplinary history. Sellers may push for a stock purchase, particularly if the pharmacy holds licenses or accreditations that are difficult to transfer, but buyers should insist on representations and warranties insurance (RWI) if a stock structure is agreed upon. Clarify upfront whether PCAB accreditation is transferable or whether a new accreditation application will be required post-closing, as this can take 6–12 months and affect operational continuity.
Purchase Price and Valuation Basis
States the proposed total purchase price, the valuation methodology used, and the allocation between tangible assets, goodwill, and any earnout component tied to post-closing prescriber retention.
Example Language
Buyer proposes a total purchase price of $[X], representing a multiple of approximately [4.0–5.5]x Seller's adjusted Seller's Discretionary Earnings (SDE) of $[Y] for the trailing twelve months ended [Date], as reflected in Buyer's preliminary analysis of Seller's financial statements. The purchase price is allocated as follows: (i) $[X1] payable in cash at closing, funded through a combination of SBA 7(a) loan proceeds and Buyer equity; (ii) a seller note of $[X2] representing approximately 10–15% of total purchase price, subordinated to SBA lender requirements, bearing interest at [rate]% per annum, payable over [36–60] months; and (iii) an earnout of up to $[X3] payable over [24] months following closing, contingent upon prescriber referral retention as described in Section [X]. The parties acknowledge that final purchase price is subject to adjustment based on due diligence findings related to regulatory compliance, cleanroom certification status, and confirmed prescriber revenue concentration.
💡 Compounding pharmacy valuations typically range from 3.5x to 6.0x SDE depending on PCAB accreditation status, sterile versus non-sterile revenue mix, cleanroom compliance maturity, and prescriber diversification. Sellers with heavy HRT, veterinary, or pain management specialization and documented recurring patient volume command the upper end of that range. Buyers should negotiate a purchase price adjustment mechanism triggered by due diligence findings — particularly if cleanroom upgrades are required to achieve USP 800 compliance, which can cost $150,000–$500,000 and should reduce enterprise value dollar-for-dollar. Earnouts tied to prescriber retention over 12–24 months are standard and should be structured around total prescription volume from key referring physicians, not net revenue, to avoid disputes over pricing changes.
Due Diligence Contingency and Access
Defines the due diligence period, the scope of information to be provided, and the specific regulatory and operational records the buyer requires access to before committing to proceed.
Example Language
Buyer shall have [45–60] calendar days from the execution of this LOI to conduct comprehensive due diligence ('Due Diligence Period'). Seller agrees to provide timely access to: (i) three years of federal and state tax returns, profit and loss statements, and balance sheets; (ii) all state pharmacy board license records including any disciplinary history, consent orders, or conditions of licensure; (iii) FDA correspondence including any Form 483 observations, warning letters, or inspection records from the preceding five years; (iv) current USP 795, 797, and 800 compliance documentation including cleanroom ISO certification records, HVAC validation reports, environmental monitoring logs, and equipment calibration records; (v) PCAB accreditation certificate and most recent accreditation survey results; (vi) a complete prescriber referral list with trailing 24-month prescription volume by referring physician; (vii) all compounding SOPs and quality assurance documentation; and (viii) all payer contracts, third-party audit correspondence, and any outstanding insurance reimbursement disputes. Buyer may extend the Due Diligence Period by an additional [15] days upon written notice if regulatory records require additional review time.
💡 The regulatory due diligence scope is non-negotiable in compounding pharmacy acquisitions. Any FDA 483 observation or state board action — even if resolved — must be fully documented and evaluated for ongoing compliance risk. Buyers should engage a pharmacy regulatory consultant or compliance attorney during due diligence, not just a general M&A attorney. Pay particular attention to beyond-use dating (BUD) documentation and batch records, as these are the most common areas of USP 797 deficiency. Prescriber referral data is often the single most important due diligence deliverable — request trailing 24 months by individual prescriber NPI number, not by practice or clinic name, to identify true concentration risk at the physician level.
Regulatory and Licensure Contingencies
Establishes closing conditions related to regulatory status, license transfers, pharmacist-in-charge succession, and any pre-closing remediation required to bring the facility into compliance.
Example Language
Closing of the transaction is expressly conditioned upon: (i) Buyer obtaining, or confirming the transferability of, all required state pharmacy board licenses and DEA registrations necessary to operate the Business in [State(s)]; (ii) Buyer identifying and designating a licensed Pharmacist-in-Charge (PIC) acceptable to the applicable state pharmacy board prior to closing, which may include Seller continuing as interim PIC pursuant to a Transition Services Agreement of no less than [6] months post-closing; (iii) no new FDA inspections, Form 483 observations, warning letters, or state board disciplinary actions being initiated against the pharmacy between the LOI execution date and closing; (iv) Seller providing written evidence that all existing FDA 483 observations, if any, have been formally responded to and closed; and (v) all cleanroom certifications, environmental monitoring programs, and USP 797/800 compliance documentation being current and valid as of the closing date.
💡 The pharmacist-in-charge transition is frequently underestimated and is one of the most operationally sensitive elements of any compounding pharmacy deal. If the buyer does not hold a pharmacist license in the applicable state, they must either hire a licensed PIC before closing or structure a transition services agreement with the seller-pharmacist. SBA lenders are increasingly scrutinizing PIC continuity plans as part of their underwriting, so buyers should document this succession plan early in the process. If the pharmacy operates in multiple states or ships compounding preparations across state lines under Section 503A, confirm that all out-of-state non-resident pharmacy licenses are current and transferable.
Exclusivity and No-Shop Period
Grants the buyer an exclusive negotiating period during which the seller agrees not to solicit or entertain competing offers.
Example Language
In consideration of Buyer's commitment to dedicate resources to due diligence and financing, Seller agrees that during the period commencing on the date of this LOI and ending [60] days thereafter ('Exclusivity Period'), Seller shall not, directly or indirectly, solicit, initiate, encourage, or participate in discussions or negotiations with any third party regarding the sale, merger, recapitalization, or other disposition of the Business or any material portion of its assets. Seller shall promptly notify Buyer if any unsolicited expression of interest is received during the Exclusivity Period. The Exclusivity Period may be extended by mutual written agreement if due diligence or financing timelines require additional time.
💡 Sixty days is standard for compounding pharmacy acquisitions given the complexity of regulatory due diligence and SBA lender underwriting timelines. Sellers with PCAB accreditation and clean regulatory records are in stronger negotiating positions and may push for a shorter 45-day exclusivity window. Buyers financing through SBA 7(a) should begin the lender engagement process simultaneously with LOI execution, as SBA underwriting for healthcare businesses frequently requires additional documentation and can add 3–6 weeks to closing timelines.
Earnout Structure for Prescriber Retention
Defines the post-closing earnout mechanism tied to retention of key prescriber referral relationships, including measurement methodology, payment schedule, and dispute resolution.
Example Language
Buyer agrees to pay Seller an earnout of up to $[X] over [24] months following the closing date, structured as follows: (i) 50% of the earnout ($[X/2]) is payable at the [12]-month anniversary of closing if aggregate prescription volume from the Top 10 referring prescribers identified in Schedule A ('Key Prescribers') equals or exceeds [80%] of the trailing 12-month volume reflected in Seller's pre-closing prescriber report; (ii) the remaining 50% of the earnout ($[X/2]) is payable at the [24]-month anniversary of closing subject to the same retention threshold measured against the prior 12-month period. Earnout amounts shall be prorated on a linear basis if Key Prescriber volume falls between [65%] and [80%] of the baseline. No earnout shall be payable for any measurement period in which aggregate Key Prescriber volume falls below [65%] of baseline. Buyer shall provide Seller with quarterly prescription volume reports by prescriber NPI during the earnout period.
💡 Prescriber earnouts are the most heavily negotiated term in compounding pharmacy LOIs. Sellers will argue that prescriber retention is partly outside their control after closing, and they are not wrong — buyers must invest in relationship transition activities, including joint visits with referring physicians and clinical education support, to protect earnout outcomes. Buyers should insist that seller participation in prescriber introductions is a contractual obligation during the transition period, not merely a best-efforts commitment. Consider including a carve-out that forgives earnout shortfalls caused by prescriber retirement, relocation, or death, while maintaining the threshold for prescribers who actively shift volume to competing pharmacies.
Seller Non-Compete and Transition Services
Establishes post-closing restrictions on the seller's ability to compete or solicit prescribers, and defines the scope and duration of any transition services the seller will provide.
Example Language
As a material inducement to Buyer's execution of this LOI and the definitive Purchase Agreement, Seller agrees to execute a Non-Competition and Non-Solicitation Agreement at closing providing that Seller shall not, for a period of [3–5] years following the closing date within a [25–50] mile radius of the Business's primary location: (i) own, operate, manage, or consult for any compounding pharmacy or specialty pharmacy engaged in therapeutic categories materially similar to those of the Business; or (ii) directly or indirectly solicit any prescriber or patient relationship of the Business. Seller further agrees to provide transition services for a period of [6–12] months post-closing, including pharmacist-in-charge coverage where required by state licensure, prescriber relationship introductions, staff training continuity, and assistance with payer credentialing transitions, compensated at a rate of $[X] per month during the transition period.
💡 Non-compete enforceability varies significantly by state, so buyers should have local counsel review the geographic scope and duration before finalizing. For compounding pharmacies where the selling pharmacist is the primary relationship holder with key prescribers, a 3–5 year non-compete is standard and supportable. The transition services agreement should be drafted as a separate exhibit to the purchase agreement and should include specific deliverables — not just a general obligation to assist — including a minimum number of prescriber introduction meetings and documented handoff of all active patient accounts. SBA lenders typically require non-competes as a closing condition.
Financing Contingency and SBA Loan Terms
States the buyer's intended financing structure, including SBA 7(a) loan parameters, equity injection requirements, and the conditions under which the financing contingency may be exercised or waived.
Example Language
Buyer intends to finance the acquisition through a combination of (i) an SBA 7(a) loan of up to $[X] from [Lender Name or TBD], (ii) a seller note of approximately $[Y] representing [10–15%] of the total purchase price subordinated to SBA lender requirements, and (iii) Buyer equity injection of not less than [10%] of the total project cost. This LOI is contingent upon Buyer obtaining a written SBA loan commitment on terms acceptable to Buyer within [30] days of LOI execution. In the event Buyer is unable to obtain acceptable SBA financing within such period, Buyer may terminate this LOI without liability upon written notice to Seller, and the parties shall have no further obligations hereunder except as expressly stated. Buyer agrees to submit a complete SBA loan package to its preferred lender within [5] business days of LOI execution.
💡 SBA 7(a) financing is the dominant structure for compounding pharmacy acquisitions in the $1M–$3M SDE range. Lenders will require the pharmacy to demonstrate stable or growing revenue, a clean regulatory history, and a viable PIC succession plan as part of underwriting. The seller note must be on full standby during the SBA loan term, which sellers occasionally resist — address this expectation early to avoid renegotiation. Buyers should obtain a pre-qualification letter from an SBA lender experienced in healthcare services before submitting an LOI, as this strengthens the offer and demonstrates financing credibility to sellers who have concerns about deal certainty.
Confidentiality and Information Use
Protects the seller's proprietary business information, prescriber relationships, and regulatory records shared during due diligence from unauthorized disclosure or competitive misuse.
Example Language
Buyer acknowledges that all information provided by Seller in connection with this LOI and the due diligence process, including but not limited to financial records, prescriber lists, proprietary formulation data, patient volume data, compounding SOPs, regulatory correspondence, and employee information ('Confidential Information'), is strictly confidential and shall be used solely for the purpose of evaluating the proposed transaction. Buyer agrees not to disclose Confidential Information to any third party other than Buyer's legal counsel, financial advisors, SBA lender, and due diligence consultants who are bound by equivalent confidentiality obligations. In the event the transaction does not close, Buyer shall promptly return or destroy all Confidential Information and shall not use prescriber relationship data or proprietary formulation information for any competitive purpose. This confidentiality obligation shall survive termination of this LOI for a period of [3] years.
💡 Prescriber lists and proprietary formulation data are among the most competitively sensitive assets of any compounding pharmacy. Sellers should insist that access to prescriber NPI-level data and formulation SOPs be restricted to a named list of buyer representatives until a definitive agreement is executed. Buyers who are strategic acquirers — such as existing pharmacy operators — should expect sellers to require additional confidentiality protections or to stage information disclosure, releasing the most sensitive operational data only after regulatory and financial due diligence is substantially complete.
Prescriber Retention Earnout Threshold
The percentage of pre-closing Key Prescriber referral volume that must be maintained post-closing to trigger earnout payments is the single most contested term in compounding pharmacy LOIs. Sellers push for lower retention thresholds (65–70%) while buyers seek higher bars (80–85%). The baseline measurement period, the definition of Key Prescribers, and the exclusion of prescribers lost due to retirement or relocation versus competitive switching must all be precisely defined to avoid post-closing disputes.
Pharmacist-in-Charge Transition Structure
Whether the selling pharmacist remains as interim PIC under a paid transition services agreement, how long that obligation lasts, and what happens if the buyer's designated PIC fails to obtain licensure before closing are all critical points. State pharmacy boards in some jurisdictions will not allow an ownership change without simultaneous PIC designation, which creates a hard deadline that must be embedded in the closing conditions. Sellers seeking a clean exit should negotiate a defined and compensated PIC transition period rather than an open-ended obligation.
Purchase Price Adjustment for Cleanroom Compliance Gaps
If due diligence reveals that the pharmacy's cleanroom infrastructure does not meet current USP 797 or USP 800 standards, buyers should negotiate a dollar-for-dollar purchase price reduction equal to the estimated cost of remediation, supported by an independent engineering assessment. Sellers will resist large adjustments, often arguing that existing practices are grandfathered or that proposed USP revisions make current standards uncertain. Establishing a cap on downward adjustments and an agreed-upon assessment methodology in the LOI prevents this from becoming a deal-breaking issue at closing.
Regulatory Tail Risk Allocation and Indemnification Cap
Who bears the cost of regulatory actions initiated after closing but based on pre-closing conduct — such as an FDA inspection triggered by a complaint filed before the sale — is a major risk allocation question in compounding pharmacy deals. Buyers should insist on seller indemnification for pre-closing regulatory liabilities with a meaningful cap (often 15–25% of purchase price) and a survival period of at least 3–5 years given FDA enforcement timelines. Sellers should negotiate carve-outs for regulatory changes in law that were not foreseeable at closing.
Revenue Concentration Representation and Warranty
Sellers should represent that no single prescriber accounts for more than a specified percentage (typically 20–25%) of total annual prescription revenue, and that the prescriber referral data provided during due diligence is accurate and complete. If the pharmacy has meaningful concentration — a common reality in smaller compounding practices — buyers should structure this as a known risk priced into the earnout structure rather than a binary deal condition, and document the agreed concentration level in the LOI to prevent misrepresentation claims at closing.
PCAB Accreditation Status and Transferability
Whether PCAB accreditation transfers with the pharmacy assets or must be reapplied for under new ownership significantly affects post-closing operational continuity and market positioning. Some buyers have been surprised to discover that PCAB treats ownership changes as triggering events requiring a new accreditation survey, which can take 6–12 months. The LOI should specify who bears the cost of maintaining or re-obtaining accreditation, whether the seller is obligated to support the re-accreditation process, and how an accreditation gap period affects earnout calculations.
Non-Compete Geographic Scope and Duration
For compounding pharmacies with a regional or statewide prescriber base — common in HRT, veterinary, or pain management specializations where formulations are shipped across county lines — a standard 25-mile non-compete radius may be insufficient to protect the buyer's investment. Buyers in these cases should negotiate a statewide or multi-state non-compete aligned with the pharmacy's actual prescriber geography, while sellers should push back on overly broad restrictions that limit their ability to consult or practice pharmacy in any capacity after the sale.
Find Compounding Pharmacy Businesses to Acquire
Enough information to write a strong LOI on day one — free to join.
Not necessarily to sign an LOI or complete the acquisition, but a licensed Pharmacist-in-Charge must be designated and approved by the state pharmacy board before the pharmacy can legally operate under new ownership. Buyers who are not licensed pharmacists — including private equity groups and entrepreneurial investors — routinely acquire compounding pharmacies by hiring or partnering with a qualified PIC. SBA lenders will scrutinize the PIC succession plan as part of underwriting, so this must be resolved well before closing. Many deals include a transition services agreement where the selling pharmacist serves as interim PIC for 6–12 months while the buyer's designated pharmacist completes any required state licensure steps.
Seller's Discretionary Earnings for a compounding pharmacy starts with net income and adds back owner compensation, owner benefits, depreciation and amortization, one-time or non-recurring expenses, and any personal expenses run through the business. Common add-backs specific to compounding pharmacies include above-market owner pharmacist salary (if the owner is paying themselves a salary significantly above what a hired PIC would cost), one-time cleanroom upgrade costs or equipment purchases expensed in a single year, and non-recurring regulatory consultant fees. Buyers should normalize the PIC salary at market rate — typically $130,000–$160,000 annually for a licensed pharmacist-in-charge in most markets — when calculating adjusted SDE, as this directly affects the valuation multiple and the SBA loan amount.
The most deal-threatening regulatory issues are active FDA warning letters, unresolved Form 483 observations citing systemic sterility failures, state board consent orders restricting compounding categories, and DEA registration issues related to controlled substance handling. Outstanding consent decrees that prohibit certain compounding activities can render a significant portion of the pharmacy's revenue base legally unachievable by the buyer, which typically makes the deal non-financeable under SBA guidelines. Minor or resolved citations are generally manageable if the seller can demonstrate documented corrective action and a clean subsequent inspection record. Buyers should engage a pharmacy regulatory attorney — not a general healthcare attorney — to review all FDA and state board correspondence during due diligence.
Most compounding pharmacy acquisitions in the $1M–$5M revenue range take 4–9 months from LOI to closing. The primary timeline drivers are SBA lender underwriting (typically 60–90 days), state pharmacy board license transfer or new PIC designation (30–90 days depending on jurisdiction), and due diligence complexity related to regulatory compliance documentation and prescriber data analysis. Deals involving sterile compounding facilities or multi-state operations tend to take longer due to the depth of cleanroom and regulatory due diligence required. Buyers using conventional financing rather than SBA can close faster, but SBA financing dominates this market segment given the working capital and real estate financing flexibility it provides.
A standard earnout in a compounding pharmacy deal is structured over 12–24 months, tied to retention of the top 5–10 prescribers by volume, and sized at 10–20% of total purchase price. The most defensible earnout structures measure prescription unit volume by individual prescriber NPI rather than net revenue, use a tiered payout (e.g., 100% of earnout at 85%+ retention, 50% at 70–85%, zero below 70%), and exclude prescribers lost due to retirement or relocation from the denominator. Buyers should negotiate the right to quarterly volume reporting and audit rights over prescriber data. Sellers should insist that earnout calculations be adjusted if the buyer materially changes the pharmacy's pricing, formulary, or prescriber outreach programs in ways that negatively affect referral volume independent of relationship quality.
Asset purchases are strongly preferred by buyers because they allow selective assumption of liabilities, avoiding inherited regulatory tail risk from pre-closing FDA inspections, state board actions, or third-party payer audits. Stock purchases are occasionally preferred by sellers when the pharmacy holds difficult-to-transfer licenses, PCAB accreditation, or favorable payer contracts that would lapse upon an asset sale. If a stock purchase is required, buyers should insist on representations and warranties insurance with a policy limit covering at least 15–20% of enterprise value, a robust indemnification escrow held for 24–36 months post-closing, and specific regulatory compliance representations with extended survival periods. SBA lenders will finance both structures but may require additional representations and compliance documentation for stock deals.
More Compounding Pharmacy Guides
More LOI Templates
Get enough diligence data to write a confident LOI from day one.
Create your free accountNo credit card required
For Buyers
For Sellers